A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Rello J., Krenn C., Locker G., Pilger E., Madl C., Balica L., ...More

CRITICAL CARE, vol.21, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 21
  • Publication Date: 2017
  • Doi Number: 10.1186/s13054-017-1601-9
  • Journal Name: CRITICAL CARE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Pseudomonas aeruginosa, Vaccination, Immunity, Immunocompromised host, Bacterial infections, Mortality, PROTEIN-F, OPRF-OPRI, AERUGINOSA, IMMUNOGENICITY, SAFETY, INFECTION
  • Akdeniz University Affiliated: No

Abstract

Background: Currently, no vaccine against Pseudomonas is available. IC43 is a new, recombinant, protein (OprF/I)-based vaccine against the opportunistic pathogen, Pseudomonas aeruginosa, a major cause of serious hospital-acquired infections. IC43 has proven immunogenicity and tolerability in healthy volunteers, patients with burns, and patients with chronic lung diseases. In order to assess the immunogenicity and safety of IC43 in patients who are most at risk of acquiring Pseudomonas infections, it was evaluated in mechanically ventilated ICU patients.